Rhythm Pharmaceuticals achieved an average 18.8% reduction in body mass index (BMI) for patients with a rare form of obesity after two years of treatment with setmelanotide. The data expands the clinical profile of the drug following an acquisition approach from AstraZeneca earlier this month. Investors are closely monitoring the obesity drug market as pharmaceutical companies expand treatments for specialized genetic and neuroendocrine conditions.
Rhythm Reports Weight Loss in Rare Obesity Trial
Rhythm Pharmaceuticals announced that its drug setmelanotide showed clinically meaningful body weight reduction in patients with brain damage-related obesity after two years of therapy. Participants treated continuously with the therapy achieved an average 18.8 percent reduction in body mass index.
Insights:










